Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Recent findings from the MARS 2 trial challenge traditional treatment protocols for mesothelioma, indicating that chemotherapy alone may offer improved outcomes over combined surgical approaches. Discover why experts are re-evaluating long-standing surgical treatments.
Medical Oncology September 25th 2023
Dana-Farber Cancer Institute
Discover how the FLAURA2 trial’s findings on combination therapy could revolutionize initial treatment plans for NSCLC patients with EGFR mutations. Learn more about the significant extension in progression-free survival and its potential clinical implications.
DocWire News
The targeted chemotherapy pill AOH1996, developed by the City of Hope, has shown promising results in preclinical research by targeting PCNA, a protein once thought to be too challenging for targeted therapy. Explore the potential of this novel approach as it advances to phase 1 clinical trials.
Medical Oncology August 14th 2023
Cancer Care Business Exchange (CBEx)
The chemotherapy shortage in the US is a pressing issue that demands a reevaluation of health policies. Dive deeper into the potential strategies for mitigating its impact, from creating a market for high-quality generics to convening a multi-stakeholder task force.
Medical Oncology August 7th 2023
Malnutrition is a pressing issue in cancer care, with studies highlighting its significant influence on treatment outcomes and mortality rates. Exploring strategies for prevention, treatment, and ongoing support is vital to improve patient quality of life and success in cancer treatment.
Medical Oncology August 1st 2023
Journal of Clinical Pathways
This comprehensive research highlights favorable outcomes with Cigna’s home-redirection program for pegfilgrastim administration in CIN prophylaxis, including a 32% reduction in specific complications. Explore how this study may influence future healthcare delivery models, enhancing both clinical efficacy and affordability.
Hematology/Oncology August 1st 2023